Form 4 for CRL Charles River Laboratories
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-15 · accession 0001127602-23-005808 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-17 | 2023-02-15 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | S - Sale | $250.00 | -20.0K | 216.6K | -8% | -$5.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-15 | S | D | 19,892 | $250.00 | 216,702 | D | — | — | (F2) On 2/01/2023: 3,672 shares were transferred from the 2021 GRAT account to Direct Holdings. |
| 2 | Common | Common Stock | 2023-02-15 | S | D | 108 | $250.16 | 216,594 | D | — | — | (F2) On 2/01/2023: 3,672 shares were transferred from the 2021 GRAT account to Direct Holdings. |